Please use this identifier to cite or link to this item:
Comparison of serologic assays for Middle East respiratory syndrome coronavirus
Harvey, R
Mattiuzzo, G
Hassall, M
Sieberg, A
Müller, M
Drosten, C
Rigsby, P
Oxenford, C
Caly, L
Li, C
Zhao, L
Tan, W
Peiris, M
Perera, M
Drosten, C
Kang, C
Wang, J
Haagmans, B
Okba, N
Gopal, R
Myhill, S
Thornburg, N
Acceso Abierto
Middle East respiratory syndrome coronavirus (MERS-CoV) was detected in humans in 2012. Since then, sporadic outbreaks with primary transmission through dromedary camels to humans and outbreaks in healthcare settings have shown that MERS-CoV continues to pose a threat to human health. Several serologic assays for MERS-CoV have been developed globally. We describe a collaborative study to investigate the comparability of serologic assays for MERS-CoV and assess any benefit associated with the introduction of a standard reference reagent for MERS-CoV serology. Our study findings indicate that, when possible, laboratories should use a testing algorithm including >2 tests to ensure correct diagnosis of MERS-CoV. We also demonstrate that the use of a reference reagent greatly improves the agreement between assays, enabling more consistent and therefore more meaningful comparisons between results.
Emerging Infectious Diseases
Appears in Collections:Artículos científicos

Upload archives

File SizeFormat 
108521.pdf816.46 kBAdobe PDFView/Open